In a study by Choi et al., it has been suggested that AR-positive TNBCs represent a specific subset of breast cancer with poorer clinical outcome, and AR blockade could be a potential endocrine therapy for patients with AR-positive TNBCs [11]. This evidence concerns the gene AR and breast carcinoma.